Inari Medical (NARI)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Inari Medical (NARI)
Inari Medical Inc is a medical device company focused on developing products to treat patients suffering from Chronic Venous Disease. Its product portfolio includes; ClotTriever, for the removal of the clot from peripheral blood vessels and treats patients suffering from deep vein thrombosis. The FlowTriever System product is used for the treatment of pulmonary embolism, InThrill system to treat small vessel thrombosis, LimFlow system and others. Geographically, the company generates majority of its revenue from United States and rest from International markets.
Key Insights
Critical company metrics and information
Share Price
$51.85Market Cap
$3.04 BillionTotal Outstanding Shares
58.54 Million SharesTotal Employees
1,300Dividend
No dividendIPO Date
May 22, 2020SIC Description
Surgical & Medical Instruments & ApparatusHomepage
https://www.inarimedical.com
Historical Stock Splits
Execution Date | Split Amount |
---|---|
No Historical Stock Splits |
Cash Flow Statement
July 1, 2023 to June 30, 2024
Metric | Value |
---|---|
Net Cash Flow From Operating Activities | $27.41 Million |
Net Cash Flow From Financing Activities | $681000.00 |
Net Cash Flow From Financing Activities, Continuing | $681000.00 |
Net Cash Flow From Operating Activities, Continuing | $27.41 Million |
Net Cash Flow From Investing Activities, Continuing | $-14.49 Million |
Exchange Gains/Losses | $125000.00 |
Net Cash Flow, Continuing | $12.23 Million |
Net Cash Flow | $12.36 Million |
Net Cash Flow From Investing Activities | $-14.49 Million |
Income Statement
July 1, 2023 to June 30, 2024
Metric | Value |
---|---|
Income Tax Expense/Benefit | $21.96 Million |
Cost Of Revenue | $70.37 Million |
Net Income/Loss Attributable To Parent | $-57.05 Million |
Basic Earnings Per Share | $0.98 |
Operating Income/Loss | $-46.80 Million |
Costs And Expenses | $582.57 Million |
Operating Expenses | $523.91 Million |
Selling, General, and Administrative Expenses | $406.99 Million |
Net Income/Loss | $-57.05 Million |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
Diluted Average Shares | $114.90 Million |
Revenues | $547.47 Million |
Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
Diluted Earnings Per Share | $0.99 |
Net Income/Loss Available To Common Stockholders, Basic | $-57.05 Million |
Benefits Costs and Expenses | $582.57 Million |
Income/Loss From Continuing Operations Before Tax | $-35.09 Million |
Research and Development | $96.17 Million |
Gross Profit | $477.11 Million |
Basic Average Shares | $115.72 Million |
Income/Loss From Continuing Operations After Tax | $-57.05 Million |
Preferred Stock Dividends And Other Adjustments | $0.00 |
Balance Sheet
July 1, 2023 to June 30, 2024
Metric | Value |
---|---|
Noncurrent Liabilities | $110.86 Million |
Equity | $423.81 Million |
Current Assets | $249.35 Million |
Other Current Assets | $199.99 Million |
Noncurrent Assets | $423.58 Million |
Inventory | $49.36 Million |
Liabilities | $249.12 Million |
Current Liabilities | $138.26 Million |
Assets | $672.93 Million |
Liabilities And Equity | $672.93 Million |
Intangible Assets | $143.11 Million |
Fixed Assets | $23.00 Million |
Other Non-current Assets | $257.47 Million |
Equity Attributable To Noncontrolling Interest | $0.00 |
Accounts Payable | $16.38 Million |
Equity Attributable To Parent | $423.81 Million |
Wages | $54.36 Million |
Other Current Liabilities | $67.52 Million |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
â“’ 2024 Financhle. All Rights Reserved.